文献速递肿瘤 PET/CT核素与放射性配体治疗

中国核医学发展概况及其诊疗一体化进展

Landscape of Nuclear Medicine in China and Its Progress on Theranostics.
PubMed 文献 · J Nucl Med · 2024-05-06

放射性药物产业链初步形成,PET/CT等设备实现国产并出口;68Ga与177Lu标记的肿瘤靶向探针在越来越多医院用于诊疗一体化,并有望获国家药品监督管理局批准。

要点

  • 放射性药物产业链初步形成,PET/CT等先进设备已国产化并出口海外。
  • 68Ga与177Lu标记肿瘤靶向探针在越来越多医院用于诊疗一体化,并有望获国家药品监督管理局批准。

核心结论

  • 随着中国政府发布《医用同位素中长期发展规划(2021-2035年)》,中国核医学未来10-20年具有很大发展潜力。
  • 随着自主创新制造兴起,放射性药物短缺将得到有效缓解。
  • 预计到2035年中国核医学规模至少翻一番,覆盖所有高级别医院,并实现「一县一科」目标。

研究设计与样本

  • 本文为综述,检索范围与文献纳入方法原文未报告。

主要发现

  • 过去十年放射性药物产业发展迅速,临床使用与基础研究用各类放射性药物的完整产业链初步形成。
  • PET/CT等先进设备已实现国产制造,甚至出口到国外。
  • 筛选与合成新靶点探针并转化至临床的研究受到更多关注,多种具有潜在临床价值的新示踪剂得到深入研究。
  • 68Ga与177Lu标记的肿瘤靶向探针等已在越来越多医院用于诊疗一体化,并有望在国家药品监督管理局批准后得到帮助。

关键数值与推荐

  • 原文未报告具体诊断标准、推荐条款或阈值。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nuclear medicine in China started in 1956 and, with the rapid development of the economy and continuous breakthroughs in precision medicine, has made significant progress in recent years. Almost 13,000 staff members in nearly 1,200 hospitals serve more than 3.9 million patients each year. Over the past decade, the radiopharmaceutical industry has developed rapidly, with the initial formation of a complete industrial chain of production of various radiopharmaceuticals for both clinical use and basic research. Advanced equipment such as PET/CT scanners is being manufactured domestically and even installed abroad. Recently, research into screening and synthesizing new target probes and their translation into the clinic has gained more attention, with various new tracers with potential clinical value being thoroughly studied. Simultaneously, 68Ga- and 177Lu-labeled tumor-targeted probes and others have been implemented for theranostics in an increasing number of hospitals and would be helped by approval from the National Medical Products Administration. Over the next 10-20 y, with the launch of the Mid- and Long-Term Development Plan for Medical Isotopes (2021-2035) by the Chinese government, there is great potential for nuclear medicine in China. With the rise in independent innovation in manufacturing, the shortage of radiopharmaceuticals will be effectively curtailed. We anticipate that the scale of nuclear medicine will at least double by 2035, covering all high-grade hospitals and leading to the aim of "one county, one department" in China.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Yang W, Kang F, Chen Y, et al. Landscape of Nuclear Medicine in China and Its Progress on Theranostics. J Nucl Med. 2024. PMID: 38719237. doi:10.2967/jnumed.123.266968

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。